HC Wainwright Reiterates Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 452.49% from the stock’s current price.

A number of other analysts also recently issued reports on the company. Wells Fargo & Company dropped their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Wedbush reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Finally, UBS Group decreased their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.24.

Zentalis Pharmaceuticals Trading Up 1.1 %

Zentalis Pharmaceuticals stock opened at $1.81 on Thursday. Zentalis Pharmaceuticals has a 1-year low of $1.61 and a 1-year high of $16.27. The firm has a market capitalization of $128.99 million, a PE ratio of -0.73 and a beta of 1.75. The firm’s 50 day simple moving average is $2.04 and its 200 day simple moving average is $2.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. The business had revenue of $26.90 million during the quarter. Research analysts forecast that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Insider Transactions at Zentalis Pharmaceuticals

In related news, Director Jan Skvarka acquired 60,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Friday, January 31st. The shares were purchased at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the purchase, the director now owns 149,551 shares of the company’s stock, valued at $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ingmar Bruns acquired 20,000 shares of the firm’s stock in a transaction dated Thursday, February 6th. The stock was bought at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the acquisition, the insider now owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. This trade represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Erste Asset Management GmbH purchased a new position in Zentalis Pharmaceuticals during the 3rd quarter valued at about $37,000. Paloma Partners Management Co bought a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter worth approximately $37,000. Corton Capital Inc. purchased a new position in shares of Zentalis Pharmaceuticals during the fourth quarter valued at approximately $32,000. Captrust Financial Advisors bought a new position in shares of Zentalis Pharmaceuticals during the fourth quarter valued at approximately $33,000. Finally, Prudential Financial Inc. purchased a new stake in Zentalis Pharmaceuticals in the fourth quarter worth $39,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.